{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["EGFR", "Quinazolinone", "antiproliferative", "kinase inhibitor", "structure-activity relationship"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34074193", "DateCompleted": {"Year": "2021", "Month": "08", "Day": "23"}, "DateRevised": {"Year": "2024", "Month": "04", "Day": "02"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.1080/14756366.2021.1933466"], "Journal": {"ISSN": "1475-6374", "JournalIssue": {"Volume": "36", "Issue": "1", "PubDate": {"Year": "2021", "Month": "Dec"}}, "Title": "Journal of enzyme inhibition and medicinal chemistry", "ISOAbbreviation": "J Enzyme Inhib Med Chem"}, "ArticleTitle": "Synthesis and preliminary structure-activity relationship study of 3-methylquinazolinone derivatives as EGFR inhibitors with enhanced antiproliferative activities against tumour cells.", "Pagination": {"StartPage": "1205", "EndPage": "1216", "MedlinePgn": "1205-1216"}, "Abstract": {"AbstractText": ["In this paper, a set of 3-methylquniazolinone derivatives were designed, synthesised, and studied the preliminary structure-activity relationship for antiproliferative activities. All target compounds performed significantly inhibitory effects against wild type epidermal growth factor receptor tyrosine kinase (EGFR<sup>wt</sup>-TK) and tumour cells (A431, A549, MCF-7, and NCI-H1975). In particular, compound <b>4d</b> 3-fluoro-<i>N</i>-(4-((3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)methoxy)phenyl)benzamide showed higher antiproliferative activities against all tumour cells than Gefitinib (IC<sub>50</sub> of 3.48, 2.55, 0.87 and 6.42\u2009\u03bcM, respectively). Furthermore, compound <b>4d</b> could induce apoptosis of MCF-7 cells and arrest in G2/M phase at the tested concentration. Molecular docking and ADMET studies showed that compound <b>4d</b> could closely form many hydrogen bonds with EGFR<sup>wt</sup>-TK. Therefore, compound <b>4d</b> is potential to develop as novel anti-cancer drug."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmaceutical Sciences, Guizhou University, Guiyang, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, China."}], "LastName": "Zhang", "ForeName": "Yan", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmaceutical Sciences, Guizhou University, Guiyang, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, China."}], "LastName": "Wang", "ForeName": "Qin", "Initials": "Q"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Shizhen College of Guizhou University of Traditional Chinese Medicine, Guiyang, China."}], "LastName": "Li", "ForeName": "Luolan", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmaceutical Sciences, Guizhou University, Guiyang, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, China."}], "LastName": "Le", "ForeName": "Yi", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmaceutical Sciences, Guizhou University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, China."}], "LastName": "Liu", "ForeName": "Li", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmaceutical Sciences, Guizhou University, Guiyang, China."}], "LastName": "Yang", "ForeName": "Jing", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Light Industry and Chemical Engineering, Guangdong University of Technology, Guangzhou, China."}], "LastName": "Li", "ForeName": "Yongliang", "Initials": "Y"}, {"Identifier": ["0000-0001-5103-5009"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute for Biomedical Materials and Devices (IBMD), Faculty of Science, University of Technology Sydney, Sydney, Australia."}], "LastName": "Bao", "ForeName": "Guochen", "Initials": "G"}, {"Identifier": ["0000-0003-3703-6704"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmaceutical Sciences, Guizhou University, Guiyang, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, China."}], "LastName": "Yan", "ForeName": "Longjia", "Initials": "L"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "J Enzyme Inhib Med Chem", "NlmUniqueID": "101150203", "ISSNLinking": "1475-6366"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein Kinase Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Quinazolinones"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "EGFR protein, human"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "ErbB Receptors"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Cycle"}, {"QualifierName": [], "DescriptorName": "Cell Line"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": [], "DescriptorName": "Crystallography, X-Ray"}, {"QualifierName": [], "DescriptorName": "Dose-Response Relationship, Drug"}, {"QualifierName": [], "DescriptorName": "Drug Screening Assays, Antitumor"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "ErbB Receptors"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Protein Kinase Inhibitors"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Quinazolinones"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}], "CoiStatement": "No potential conflict of interest was reported by the author(s)."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Ayati A, Moghimi S, Salarinejad S, et al. . A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorg Chem 2020;99:103811.", "ArticleIdList": ["32278207"]}, {"Citation": "Roskoski R. Jr., Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. Pharmacol Res 2020;152:104609.", "ArticleIdList": ["31862477"]}, {"Citation": "Sigismund S, Avanzato D, Lanzetti L.. Emerging functions of the EGFR in cancer. Mol Oncol 2018;12:3\u201320.", "ArticleIdList": ["PMC5748484", "29124875"]}, {"Citation": "Xu X, Mao L, Xu W, et al. . AC0010, an irreversible EGFR inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance in animal models and lung cancer patients. Mol Cancer Ther 2016;15:2586\u201397.", "ArticleIdList": ["27573423"]}, {"Citation": "Lu X, Yu L, Zhang Z, et al. . Targeting EGFR(L858R/T790M) and EGFR(L858R/T790M/C797S) resistance mutations in NSCLC: current developments in medicinal chemistry. Med Res Rev 2018;38:1550\u201381.", "ArticleIdList": ["29377179"]}, {"Citation": "Lee DH. Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): the road to a success, paved with failures. Pharmacol Ther 2017;174:1\u201321.", "ArticleIdList": ["28167215"]}, {"Citation": "Jia Y, Yun CH, Park E, et al. . Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature 2016;534:129\u201332.", "ArticleIdList": ["PMC4929832", "27251290"]}, {"Citation": "Mhaske SB, Argade NP.. The chemistry of recently isolated naturally occurring quinazolinone alkaloids. Tetrahedron 2006;62:9787\u2013826."}, {"Citation": "Auti PS, George G, Paul AT.. Recent advances in the pharmacological diversification of quinazoline/quinazolinone hybrids. RSC Adv 2020;10:41353\u201392.", "ArticleIdList": ["PMC9057921", "35516563"]}, {"Citation": "Shang XF, Morris-Natschke SL, Yang GZ, et al. . Biologically active quinoline and quinazoline alkaloids part II. Med Res Rev 2018;38:1614\u201360.", "ArticleIdList": ["PMC6105521", "29485730"]}, {"Citation": "Shang XF, Morris-Natschke SL, Liu YQ, et al. . Biologically active quinoline and quinazoline alkaloids part I. Med Res Rev 2018;38:775\u2013828.", "ArticleIdList": ["PMC6421866", "28902434"]}, {"Citation": "Zayed MF, Rateb HS, Ahmed S, et al. . Quinazolinone-amino acid hybrids as dual inhibitors of EGFR kinase and tubulin polymerization. Molecules 2018;23:1699\u2013716.", "ArticleIdList": ["PMC6100557", "30002297"]}, {"Citation": "Kong X-F, Guo X-Y, Gu Z-Y, et al. . Silver(i)-catalyzed selective hydroalkoxylation of C2-alkynyl quinazolinones to synthesize quinazolinone-fused eight-membered N,O-heterocycles. Org Chem Front 2020;7:2055\u201362."}, {"Citation": "Patel HM, Pawara R, Ansari A, et al. . Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle. Bioorg Med Chem 2017;25:2713\u201323.", "ArticleIdList": ["28366268"]}, {"Citation": "Ghorab MM, Abdel-Kader MS, Alqahtani AS, et al. . Synthesis of some quinazolinones inspired from the natural alkaloid L-norephedrine as EGFR inhibitors and radiosensitizers. J Enzyme Inhib Med Chem 2021;36:218\u201337.", "ArticleIdList": ["PMC7781899", "33357002"]}, {"Citation": "Yan L, Che X, Bai X, et al. . Syntheses of novel diaryl[d,f] [1,3]diazepines via one-pot Suzuki coupling followed by direct ring closure with carboxylic acids. Mol Divers 2012;16:489\u2013501.", "ArticleIdList": ["22752672"]}, {"Citation": "Yan L, Wang H, Chen Y, et al. . Synthesis and structure-activity relationship study of diaryl[d,f][1,3]diazepines as potential anti-cancer agents. Mol Divers 2018;22:323\u201333.", "ArticleIdList": ["29299857"]}, {"Citation": "Yan L, Li Y, Deng M, et al. . Design, synthesis and biological activities of compounds containing 1,3,4-oxadiazole or 1,3,4-thiadiazole. Chin J Org Chem 2020;40:731\u20139."}, {"Citation": "Yan L, Le Y, Chen D, et al. . Synthesis and evaluation of diaminopyrimidine derivatives as dual inhibitors of EGFR and SRC for antitumor treatment. Heterocycles 2020;100:418\u201328."}, {"Citation": "Yan L, Deng M, Chen A, et al. . Synthesis of N-pyrimidin[1,3,4]oxadiazoles and N-pyrimidin[1,3,4]-thiadiazoles from 1,3,4-oxadiazol-2-amines and 1,3,4-thiadiazol-2-amines via Pd-catalyzed heteroarylamination. Tetrahedron Lett 2019;60:1359\u201362."}, {"Citation": "Le Y, Zhang Y, Wang Q, et al. . Microwave-assisted synthesis of phenylpyrimidine derivatives via Suzuki-Miyaura reactions in water. Tetrahedron Lett 2021;68:152903."}, {"Citation": "Le Y, Gan Y, Fu Y, et al. . Design, synthesis and in\u00a0vitro biological evaluation of quinazolinone derivatives as EGFR inhibitors for antitumor treatment. J Enzyme Inhib Med Chem 2020;35:555\u201364.", "ArticleIdList": ["PMC7006757", "31967481"]}, {"Citation": "Shao L-H, Fan S-L, Meng Y-F, et al. . Design, synthesis, biological activities and 3D-QSAR studies of quinazolinone derivatives containing hydrazone structural units. New J Chem 2021;45:4626\u201331."}, {"Citation": "Altarejos J, Sucunza D, Vaquero JJ, et al. . Practical solvent-free microwave-assisted hydroboration of alkynes. Eur J Org Chem 2020;2020:3024\u20139."}, {"Citation": "Kuramochi T, Kakefuda A, Yamada H, et al. . Synthesis and structure-activity relationships of phenoxypyridine derivatives as novel inhibitors of the sodium-calcium exchanger. Bioorg Med Chem 2004;12:5039\u201356.", "ArticleIdList": ["15351388"]}, {"Citation": "Li Y, Yan L, Cai J, et al. . Development of novel theranostic agents for in\u00a0vivo amyloid imaging and protective effects on human neuroblastoma cells. Eur J Med Chem 2019;181:111585.", "ArticleIdList": ["31404860"]}, {"Citation": "Zhang Y, Chen L, Xu H, et al. . 6,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells. Eur J Med Chem 2018;147:77\u201389.", "ArticleIdList": ["29421573"]}, {"Citation": "D'Arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int 2019;43:582\u201392.", "ArticleIdList": ["30958602"]}, {"Citation": "Xie Z, Wu K, Wang Y, et al. . Discovery of 4,6-pyrimidinediamine derivatives as novel dual EGFR/FGFR inhibitors aimed EGFR/FGFR1-positive NSCLC. Eur J Med Chem 2020;187:111943.", "ArticleIdList": ["31846829"]}, {"Citation": "Zhang Y, Chen L, Li X, et al. . Novel 4-arylaminoquinazolines bearing N,N-diethyl(aminoethyl)amino moiety with antitumour activity as EGFR(wt)-TK inhibitor. J Enzyme Inhib Med Chem 2019;34:1668\u201377.", "ArticleIdList": ["PMC6758725", "31530043"]}, {"Citation": "Park JH, Liu Y, Lemmon MA, et al. . Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Biochem J 2012;448:417\u201323.", "ArticleIdList": ["PMC3507260", "23101586"]}, {"Citation": "Jia CY, Li JY, Hao GF, et al. . A drug-likeness toolbox facilitates ADMET study in drug discovery. Drug Discov Today 2020;25:248\u201358.", "ArticleIdList": ["31705979"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "6", "Day": "2", "Hour": "5", "Minute": "31"}, {"Year": "2021", "Month": "6", "Day": "3", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "8", "Day": "24", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "6", "Day": "2"}], "PublicationStatus": "ppublish", "ArticleIdList": ["34074193", "PMC8174486", "10.1080/14756366.2021.1933466"]}}], "PubmedBookArticle": []}